PD-1/PD-L1-IN-27 is a novel small molecule inhibitor of the PD-1/PD-L1 protein-protein interaction (IC50 of = 134 nM) with anticancer and immunomodulatory/immunoregulatory activity.

PD-1/PD-L1-IN-24 is a novel small molecule inhibitor of the PD-1/PD-L1 protein-protein interaction (IC50 of = 1.6 nM) with anticancer and immunomodulatory/immunoregulatory activity.

PD-1/PD-L1-IN-25 is a novel and potent small molecule PD-1/PD-L1 inhibitor ( IC50 of = 16 nM) with anticancer and immunomodulatory/immunoregulatory activity.

Benzoic acid-d5, deuterium substitute for Benzoic acid

PD-1/PD-L1-IN-21 is a novel inhibitor of the PD-1/PD-L1 protein-protein interaction (IC50 of = 14.99 μM) with anticancer and immunomodulatory/immunoregulatory activity.

PD-1/PD-L1-IN-26 is a novel small molecule inhibitor of the PD-1/PD-L1 protein-protein interaction (IC50 of = 38 nM) with anticancer and immunomodulatory/immunoregulatory activity.

SNC-162, delta-opioid receptor agonist

17:0-22:4 PG-d5, deuterium labeled 17:0-22:4 PG

PD-1/PD-L1-IN-20 is a novel inhibitor of the PD-1/PD-L1 protein-protein interaction (IC50 of = 5.29 nM) with anticancer and immunomodulatory/immunoregulatory activity.

4-Methoxycinnamaldehyde, bioactive compound